[Visualising lymph nodes by aclarubicin bound to activated carbon particles in breast cancer surgery].
A new dosage formulation (ACR-CH), composed of aclarubicin (ACR) bound to fine activated carbon particles, has been developed for the treatment of lymph node metastases in breast cancer. ACR-CH is designed to (a) adsorb a great amount of aclarubicin and desorb in a free state; (b) distribute a greater amount of ACR for a longer period of time selectively to the regional lymph nodes; (c) be decreased in the systemic toxicity; and (d) enhance its therapeutic effect on lymph node metastases. In this clinical trial in 20 patients with breast cancer, ACR-CH was injected intra- and peritumorally just before operation for breast cancer, and we examined the extent of blackened nodes produced by ACR-CH. ACR-CH blackened about 70% of the axillary lymph nodes with cancer metastasis as well as the nodes without metastasis. In conclusion, ACR-CH will be useful for dissection of lymph nodes by visualizing the nodes during operation for breast cancer.
Imanishi
T
T
First Dept. of Surgery, Kyoto Prefectural University of Medicine.
Hagiwara
A
A
Sawai
K
K
Yamaguchi
T
T
Sakakura
C
C
Shirasu
M
M
Ohgaki
M
M
Yamasaki
J
J
Togawa
T
T
Takahashi
T
T
D015250:Aclarubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001943:Breast Neoplasms / Q000473:pathology / Q000601:surgery*; D002244:Carbon / Q000493:pharmacokinetics; D004304:Dosage Forms; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis / Q000473:pathology*; D051381:Rats
D000903:Antibiotics, Antineoplastic; D004304:Dosage Forms; D002244:Carbon; D015250:Aclarubicin